Journal of Cachexia, Sarcopenia and Muscle
© Springer-Verlag 2012
10.1007/s13539-012-0070-x

Erratum

Erratum to: Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference

N. Ebner1, C. G. Werner2, W. Doehner1, 2, S. D. Anker1, 3 and S. von Haehling1, 4 Contact Information

(1)  Department of Cardiology, Applied Cachexia Research, Charité Medical School, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
(2)  Centre for Stroke Research Berlin, Charité Medical School, Berlin, Germany
(3)  Centre for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy
(4)  Centre for Cardiovascular Research (CCR), Charité Medical School, Campus Mitte, Berlin, Germany

Contact Information S. von Haehling
Email: stephan.von.haehling@web.de

Published online: 22 May 2012


Without Abstract
The online version of the original article can be found at http://dx.doi.org/10.1007/s13539-012-0061-y.
The online version of the original article can be found at http://dx.doi.org/10.1007/s13539-012-0061-y.

Erratum to: J Cachexia Sarcopenia Muscle

DOI 10.1007/s13539-012-0061-y

The report of the highlights from the 6th Cachexia Conference was unfortunately published without the abstract and keywords; these are supplied here.

Abstract Both cachexia and sarcopenia are associated with muscle wasting, although cachexia may also involve other tissues. Muscle wasting is encountered in the advanced stages of many chronic illnesses. Several ongoing pre-clinical and clinical studies are expected to ameliorate this clinical problem. This article highlights the pre-clinical and clinical studies in the field of wasting disorders that were presented at the 6th Cachexia Conference in Milan, Italy, in December 2011. Effective treatments are urgently needed in order to improve the patients’ survival and quality of life. We describe ongoing research into muscle proteolytic pathways and the principal actors in skeletal muscle wasting. Novel therapeutic approaches include interleukin-6 such as receptor antibody tocilizumab, interleukin-1 receptor antagonist such as IP 1510 or selective androgen receptor modulators such as enobosarm and LGD-4033. Other candidates embraced the anabolic/catabolic transforming agent MT-102, naturally occurring peptide hormones such as ghrelin and synthetic orally active ghrelin receptor agonist anamorelin or the erythropoietin analogues ARA284 and ARA286.

Keywords Cachexia · Wasting · Sarcopenia · Therapy

Open Access  
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.